The Dark Side of ZNF217, a Key Regulator of Tumorigenesis with Powerful Biomarker Value

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Oct 3

PMID 26431164

Citations 37

Authors

Pascale A Cohen

Caterina F Donini

Nhan T Nguyen

Hubert Lincet

Julie A Vendrell

Affiliations

Soon will be listed here.

Abstract

The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.

Citing Articles

Screening of necroptosis-related genes and evaluating the prognostic capacity, clinical value, and the effect of their copy number variations in acute myeloid leukemia.

Wen D, Yan R, Zhang L, Zhang H, Chen X, Zhou J BMC Cancer. 2025; 25(1):71.

PMID: 39806277 PMC: 11727709. DOI: 10.1186/s12885-025-13439-y.

Modulatory Effect of Cucurbitacin D from on ZNF217 Oncogene Expression in NPM-Mutated Acute Myeloid Leukemia.

Adorisio S, Fierabracci A, Cham B, Hoang V, Thuy Linh N, Nhung L Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770403 PMC: 11676938. DOI: 10.3390/ph17121561.

Enhancer-promoter hubs organize transcriptional networks promoting oncogenesis and drug resistance.

Perlman B, Burget N, Zhou Y, Schwartz G, Petrovic J, Modrusan Z Nat Commun. 2024; 15(1):8070.

PMID: 39277592 PMC: 11401928. DOI: 10.1038/s41467-024-52375-6.

Systematic decoding of cis gene regulation defines context-dependent control of the multi-gene costimulatory receptor locus in human T cells.

Mowery C, Freimer J, Chen Z, Casani-Galdon S, Umhoefer J, Arce M Nat Genet. 2024; 56(6):1156-1167.

PMID: 38811842 PMC: 11176074. DOI: 10.1038/s41588-024-01743-5.

Gene Copy Number as a Marker of Response to Standard Therapy Drugs According to ERα Status in Breast Cancer.

Rangel N, Sanchez I, Valbuena D, Rondon-Lagos M Breast Cancer (Dove Med Press). 2024; 16:127-139.

PMID: 38505863 PMC: 10950081. DOI: 10.2147/BCTT.S445753.

References

Sun G, Qin J, Qiu Y, Gao Y, Yu Y, Deng Q . Microarray analysis of gene expression in the ovarian cancer cell line HO-8910 with silencing of the ZNF217 gene. Mol Med Rep. 2011; 2(5):851-5. DOI: 10.3892/mmr_00000183. View

Buttitta L, Tanaka T, Chen A, Ko M, Fan C . Microarray analysis of somitogenesis reveals novel targets of different WNT signaling pathways in the somitic mesoderm. Dev Biol. 2003; 258(1):91-104. DOI: 10.1016/s0012-1606(03)00116-7. View

Cowger J, Zhao Q, Isovic M, Torchia J . Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene. 2006; 26(23):3378-86. DOI: 10.1038/sj.onc.1210126. View

Amiri A, Noei F, Jeganathan S, Kulkarni G, Pinke D, Lee J . eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene. 2006; 26(21):3027-40. DOI: 10.1038/sj.onc.1210101. View

Suzuki S, Egami K, Sasajima K, Ghazizadeh M, Shimizu H, Watanabe H . Comparative study between DNA copy number aberrations determined by quantitative microsatellite analysis and clinical outcome in patients with stomach cancer. Clin Cancer Res. 2004; 10(9):3013-9. DOI: 10.1158/1078-0432.ccr-03-0250. View

Thollet A, Vendrell J, Payen L, Ghayad S, Ben Larbi S, Grisard E . ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Mol Cancer. 2010; 9:291. PMC: 2996367. DOI: 10.1186/1476-4598-9-291. View

Kim W, Sharpless N . The regulation of INK4/ARF in cancer and aging. Cell. 2006; 127(2):265-75. DOI: 10.1016/j.cell.2006.10.003. View

Collins C, Rommens J, Kowbel D, Godfrey T, Tanner M, Hwang S . Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A. 1998; 95(15):8703-8. PMC: 21140. DOI: 10.1073/pnas.95.15.8703. View

Bai W, Ye X, Zhang M, Zhu H, Xi W, Huang X . MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer. 2014; 135(6):1356-68. DOI: 10.1002/ijc.28782. View

10.

Mao X, Yan M, Xue X, Zhang X, Ren H, Guo G . Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest. 2011; 91(7):1068-78. DOI: 10.1038/labinvest.2011.56. View

11.

Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S . Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009; 15(6):501-13. PMC: 2693960. DOI: 10.1016/j.ccr.2009.03.018. View

12.

Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F . DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics. 2010; 11:701. PMC: 3018478. DOI: 10.1186/1471-2164-11-701. View

13.

Wang S, Huang X, Lee C, Liu B . Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene. 2010; 29(29):4225-36. DOI: 10.1038/onc.2010.180. View

14.

Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S . A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9(6):582-9. PMC: 2396950. DOI: 10.1038/embor.2008.74. View

15.

Gyorffy B, Schafer R . Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat. 2008; 118(3):433-41. DOI: 10.1007/s10549-008-0242-8. View

16.

Banck M, Li S, Nishio H, Wang C, Beutler A, Walsh M . The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Epigenetics. 2009; 4(2):100-6. PMC: 2929765. DOI: 10.4161/epi.4.2.7953. View

17.

Renner M, Wolf T, Meyer H, Hartmann W, Penzel R, Ulrich A . Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol. 2013; 14(12):r137. PMC: 4054884. DOI: 10.1186/gb-2013-14-12-r137. View

18.

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

19.

Krig S, Miller J, Frietze S, Beckett L, Neve R, Farnham P . ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene. 2010; 29(40):5500-10. PMC: 4256946. DOI: 10.1038/onc.2010.289. View

20.

Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch F . Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 2003; 63(6):1179-82. View